Actively Recruiting
Comparison of Anticholinergic, Beta-3-Adrenergic Agonist, and Placebo Treatments for Nocturnal Urinary Symptoms in Older Women
Led by University of California, San Francisco · Updated on 2026-09-22
270
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effects of different bladder therapies on cognitive, urinary, and aging-related functional outcomes in ambulatory older women who experience urgency-predominant urinary incontinence and have normal or mildly impaired cognitive function. This randomized, double-blinded, three-arm trial compares anticholinergic bladder therapy, beta-3-adrenergic agonist therapy, and no bladder pharmacotherapy to understand their impact on these outcomes. Participants receive one of three treatments tolterodine tartrate an anticholinergic medication with behavioral self-management education, mirabegron a beta-3-adrenergic agonist with behavioral self-management education, or a placebo pill with behavioral education. Each group receives specific written guidance on timed urge suppression, lifestyle changes, and pelvic floor muscle exercises. The treatment period lasts for six months 24 weeks. During the study, participants will keep validated voiding diaries to track nocturnal urination frequency and urinary incontinence episodes. Researchers will also assess sleep quality, daytime sleepiness, depression, anxiety, and cognitive function using standardized scores and tests. The study is randomized and triple-blinded, with safety monitoring throughout. The total participation time spans the 24-week treatment period.
CONDITIONS
Brief Title
Ancillary Nocturnal Urinary Symptoms Analyses for TRIUMPH
Research Team
A
Alison Huang, MD, MAS, MPhil
A
Ann Chang
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here